Tigermed (300347.SZ) announced on September 27th that the company plans to acquire Shanghai Guanhe Medical Technology Co., Ltd. (referred to as "Guanhe Medicine") held by Dian Diagnostics Group in cash, consisting of 35.8322% equity of Guanhe Medicine, 5.2200% property shares of Zhuji Guanhe, 4.8883% property shares of Zhuji Guanhe Sanhe, 2.5500% property shares of Zhuji Guanhe, and 3.6939% equity of Guanhe Medicine held by Suzhou Yingkaixin Transport Enterprise Management Consulting Co., Ltd. (referred to as "Yingkai Suzhou").

The company plans to acquire a total of 40.5650% equity of Guanhe Medicine held by Dian Diagnostics and Suzhou Yingkaixin in cash, with a total purchase price of RMB 140.3641 million.

After the completion of this transaction, the company and its wholly-owned subsidiary Jiaxing Xinge Medical Technology Co., Ltd. (referred to as "Jiaxing Xinge") will directly and indirectly hold a total of 72.8169% equity of Guanhe Medicine, which will be consolidated into the company's financial statements.